{"DataElement":{"publicId":"6819529","version":"1","preferredName":"Benign Prostatic Hyperplasia Treatment Administered Type","preferredDefinition":"Text term that represents the kind of treatment administered for benign prostatic hyperplasia.","longName":"6819321v1.0:6819500v1.0","context":"OCG","contextVersion":"1","DataElementConcept":{"publicId":"6819321","version":"1","preferredName":"Benign Prostatic Hyperplasia Therapeutic Procedure Administered","preferredDefinition":"A non-cancerous nodular enlargement of the prostate gland.  It is characterized by the presence of epithelial cell nodules, and stromal nodules containing fibrous and smooth muscle elements.  It is the most common urologic disorder in men, causing blockage of urine flow._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._The act of having given something (e.g., a medication or test).","longName":"2443167v1.0:3284230v1.0","context":"OCG","contextVersion":"1","ObjectClass":{"publicId":"2443167","version":"1","preferredName":"Benign Prostatic Hyperplasia","preferredDefinition":"A noncancerous condition in which an overgrowth of prostate tissue pushes against the urethra and the bladder, blocking the flow of urine. Also called benign prostatic hypertrophy or BPH.","longName":"C2897","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Benign Prostatic Hyperplasia","conceptCode":"C2897","definition":"A non-cancerous nodular enlargement of the prostate gland.  It is characterized by the presence of epithelial cell nodules, and stromal nodules containing fibrous and smooth muscle elements.  It is the most common urologic disorder in men, causing blockage of urine flow.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0A400EF7-3F48-3538-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-01-17","endDate":null,"createdBy":"MAESKEB","dateCreated":"2006-01-17","modifiedBy":"ONEDATA","dateModified":"2006-01-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3284230","version":"1","preferredName":"Therapeutic Procedure Administered","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.:Given.","longName":"C49236:C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD8D766D-1F24-B777-E040-BB89AD434B22","latestVersionIndicator":"Yes","beginDate":"2011-09-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-09-22","modifiedBy":"ONEDATA","dateModified":"2011-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"HCMI:Human Cancer Models Initiative","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DCE2D52-9C26-6ADD-E053-F662850A1956","latestVersionIndicator":"Yes","beginDate":"2019-07-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-16","modifiedBy":"COOPERM","dateModified":"2019-07-26","changeDescription":"Created for Prostate Cancer request 7.1.19 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6819500","version":"1","preferredName":"BPH Treatment Type","preferredDefinition":"Something distinguishable as an identifiable class based on common qualities.","longName":"6819500v1.0","context":"OCG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other (specify)","valueDescription":"Specify Other","ValueMeaning":{"publicId":"6060199","version":"1","preferredName":"Specify Other","longName":"6060199","preferredDefinition":"Be specific about something; define clearly.: Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Specify","conceptCode":"C25685","definition":"Be specific about something; define clearly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"647D160E-2332-6209-E053-F662850A6311","latestVersionIndicator":"Yes","beginDate":"2018-02-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-02-05","modifiedBy":"ONEDATA","dateModified":"2018-02-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8DE1272E-86F3-5D2A-E053-F662850AF481","beginDate":"2019-07-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-17","modifiedBy":"ONEDATA","dateModified":"2019-07-17","deletedIndicator":"No"},{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"3104212","version":"1","preferredName":"Unknown","longName":"3104212v1.00","preferredDefinition":"Not known, observed, recorded; or reported as unknown by the data contributor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87F3C580-06F4-1DC3-E040-BB89AD434E7E","latestVersionIndicator":"Yes","beginDate":"2010-06-01","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-06-01","modifiedBy":"FINCHAMB","dateModified":"2024-01-19","changeDescription":"Concept annotated for UPitt/TCGA.  Ylu, 01/30/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8DE1272E-86FE-5D2A-E053-F662850AF481","beginDate":"2019-07-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-17","modifiedBy":"ONEDATA","dateModified":"2019-07-17","deletedIndicator":"No"},{"value":"TURP","valueDescription":"Transurethral Prostatic Resection","ValueMeaning":{"publicId":"2581124","version":"1","preferredName":"Transurethral Prostatic Resection","longName":"2581124","preferredDefinition":"Surgical procedure to remove tissue from the prostate using an instrument inserted through the urethra.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Transurethral Prostatic Resection","conceptCode":"C15343","definition":"Prostate tissue removal via a cystoscope.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-09F1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-23","endDate":null,"createdBy":"SBREXT","dateCreated":"2005-11-23","modifiedBy":"PWEST","dateModified":"2006-10-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8DE1272E-8712-5D2A-E053-F662850AF481","beginDate":"2019-07-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-17","modifiedBy":"ONEDATA","dateModified":"2019-07-17","deletedIndicator":"No"},{"value":"Dutasteride","valueDescription":"Dutasteride","ValueMeaning":{"publicId":"2576806","version":"1","preferredName":"Dutasteride","longName":"2576806","preferredDefinition":"A synthetic 4-azasteroid compound. Dutasteride competitively and specificly inhibits both 5-alpha-reductase 1 and 2 isoenzymes that convert testosterone to dihydrotestosterone. The type 2 isoenzyme is primarily active in the reproductive tissues, while the type 1 isoenzyme is also responsible for conversion of testosterone in the skin and liver. Inhibition of 5-alpha reductase leads to a reduction of dihydrotestosterone formation and subsequently prevents the enlargement of the prostate gland. Dutasteride is used in the treatment of benign prostatic hyperplasia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dutasteride","conceptCode":"C47503","definition":"A synthetic 4-azasteroid compound. Dutasteride competitively and specifically binds to isoenzymes 1 and 2 of 5 alpha-reductase, forming stable enzyme complexes and inhibiting the conversion of testosterone to 5 alpha-dihydrotestosterone (DHT); the reduction in DHT activity may mitigate or prevent enlargement of the prostate gland. The type 2 5 alpha-reductase isoenzyme is primarily active in the reproductive tissues, while the type 1 isoenzyme is also active in skin and the liver.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F913-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-07","modifiedBy":"ONEDATA","dateModified":"2005-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8DE1272E-871C-5D2A-E053-F662850AF481","beginDate":"2019-07-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-17","modifiedBy":"ONEDATA","dateModified":"2019-07-17","deletedIndicator":"No"},{"value":"Finasteride","valueDescription":"Finasteride","ValueMeaning":{"publicId":"2576856","version":"1","preferredName":"Finasteride","longName":"2576856","preferredDefinition":"A synthetic azasteroid compound.  Finasteride binds to and inhibits 5-alpha-reductase, thereby interfering with the enzymatic conversion of testosterone to 5-dihydrotestosterone, ultimately interfering with prostate growth. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Finasteride","conceptCode":"C1099","definition":"A synthetic 4-azasteroid compound. Finasteride competitively binds to and inhibits steroid type II 5-alpha-reductase in the prostate gland, liver, and skin, thereby interfering with the enzymatic conversion of testosterone to 5-dihydrotestosterone (DHT) and reducing serum DHT levels. The reduction in serum DHT levels results in diminished stimulation of androgen receptors in the nuclei of prostate cells and, so, diminished prostate cell proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F945-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8DE1272E-8726-5D2A-E053-F662850AF481","beginDate":"2019-07-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-17","modifiedBy":"ONEDATA","dateModified":"2019-07-17","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"HCMI:Human Cancer Models Initiative","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DE1272E-86DB-5D2A-E053-F662850AF481","latestVersionIndicator":"Yes","beginDate":"2019-07-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-17","modifiedBy":"COOPERM","dateModified":"2019-07-26","changeDescription":"Created for Prostate Cancer request 7.17.19 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5806857","version":"1","longName":"HCMI (Human Cancer Models Initiative)","context":"OCG","ClassificationSchemeItems":[{"publicId":"10000016","version":"1","longName":"Prostate","context":"OCG"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"If the patient was treated fo","type":"Preferred Question Text","description":"If the patient was treated for BPH, which treatments were administered?","url":null,"context":"OCG"}],"origin":"HCMI:Human Cancer Models Initiative","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DE21BD2-C8E8-1B7A-E053-F662850AD205","latestVersionIndicator":"Yes","beginDate":"2019-07-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-17","modifiedBy":"COOPERM","dateModified":"2019-07-26","changeDescription":"Created for prostate request 7.1.19 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}